Digital health and other life sciences/tech developers, particularly those producing innovative new solutions, offer dynamic opportunities for investors, in part due to the continued evolution of the US Food and Drug Administration’s (FDA’s) approach to regulatory oversight. In this article, the sixth in our Focus on Innovation Centers series, Vernessa Pollard and Michael Ryan outline four important factors that hospital and health system (HHS) innovation executives should consider when investing in companies that are developing FDA-regulated products.
